DEFA14A ·Filed Mar 13, 2026

ABT

ABBOTT LABORATORIES
NEUTRAL
Impact 3/10
Horizondays Processed6mo ago SEC0001308179-26-000065
Proxy solicitation materials
Actionable Insight • Neutral

Traders should monitor for the full proxy statement to understand the specific items up for vote, such as director elections or executive compensation, which could influence investor sentiment.

DirectionNeutral
Confidencelow
Horizondays
Final — all horizons settled through T+60d
ABT ▼ -17.69% at T+60d
NEUTRAL call ✗ call lost -17.69% · α vs SPY -28.18% · entry $109.96 → $90.50
Entry anchored
Mar 13, 03:59 PM ET
via exchange tick
T+1d
+0.69%
call +0.69% · α +0.42%
$110.72
settled 7mo ago
T+5d
-4.66%
call -4.66% · α -2.61%
$104.84
settled 7mo ago
T+20d
-8.11%
call -8.11% · α -11.89%
$101.04
settled 6mo ago
T+60d
-17.69%
call -17.69% · α -28.18%
$90.50
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

This DEFA14A filing is a definitive additional proxy soliciting material from Abbott Laboratories (ABT), indicating it contains supplementary information related to an upcoming shareholder vote. The filing appears to be routine corporate governance documentation, likely related to director elections or executive compensation, but the provided documents do not contain specific financial data or details about the vote's agenda.

Key Facts

  • Filing is a DEFA14A, which is a definitive additional proxy soliciting material.
  • Filed by the registrant (Abbott Laboratories).
  • No specific details about the shareholder vote agenda are provided in the available documents.
  • The filing is routine and relates to corporate governance.

Financial Impact

No immediate financial impact expected.

Risk Factors

  • Lack of detailed information in the filing limits the ability to assess potential market impact.
  • Shareholder votes on executive compensation or board composition could affect stock sentiment if results are unexpected.

Market Snapshot

Price
$107.91
Volume
186
Exchange
NYSE
Analyst Consensus
71% bullish (35 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001308179-26-000065
Document: 0001308179-26-000065-index-headers.html0001308179-26-000065
Document: 0001308179-26-000065-index.html0001308179-26-000065
Document: 0001308179-26-000065.txt0001308179-26-000065
22 reports for ABT
Performance horizon
80% Hit rate 4 of 5 directional calls best @ T+20▲ +17.16%Jul 1, 2026
Filters
Rows
Reports for ABT — sortable, filterable
TypeNow
Oct 2, 2026
today
ANALYST-UPGRADE
BULLISH ★ 4/10
$98.00 awaiting T+5awaiting T+5—$96.69 (−1.34%)
Sep 14, 2026
18d ago
Court Ruling
NEUTRAL ★ 1/10
$103.09 $102.98▼ −0.11%▼ −1.77%$96.69 (−6.21%)
Aug 11, 2026
7w ago
Court Ruling
NEUTRAL ★ 2/10
$109.72 $112.68▲ +2.70%▲ +3.10%$96.69 (−11.88%)
Aug 11, 2026
7w ago
Court Ruling
NEUTRAL ★ 1/10
$109.72 $112.68▲ +2.70%▲ +3.10%$96.69 (−11.88%)
Jul 31, 2026
9w ago
Institutional Cluster
MIXED ★ 4/10
$105.70 $107.81▲ +2.00%▼ −1.51%$96.69 (−8.52%)
Jul 31, 2026
9w ago
Court Ruling
NEUTRAL ★ 2/10
$105.70 $107.81▲ +2.00%▼ −1.51%$96.69 (−8.52%)
Jul 24, 2026
10w ago
Court Ruling
BULLISH ★ 5/10
$103.06 $105.61▲ +2.47%▲ +2.10%$96.69 (−6.18%)
Jul 16, 2026
11w ago
8-K
BULLISH ★ 6/10
$98.83 $100.75▲ +1.94%▲ +3.61%$96.69 (−2.17%)
Jul 14, 2026
11w ago
Court Ruling
NEUTRAL ★ 3/10
$88.96 $101.66▲ +14.28%▲ +15.57%$96.69 (+8.69%)
Jul 7, 2026
12w ago
Court Ruling
NEUTRAL ★ 1/10
$95.84 $88.96▼ −7.18%▼ −7.73%$96.69 (+0.89%)
Showing 10 of 22

US Market Status

Market Closed — Opens in 45m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access